U.S. gives Johnson & Johnson's COVID-19 vaccine a timeout

Out of an abundance of caution, the FDA and CDC have recommended a pause in the use of the only one-dose coronavirus vaccine available in the U.S. right now.

| More on:
health worker wearing personal protective equipment and gesturing stop with her hands

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The third coronavirus vaccine authorized for emergency use in the United States is going to sit in the corner by itself for a little while. On Tuesday morning, the Centers for Disease Control and Prevention and the Food and Drug Administration issued a joint statement regarding Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine.

The agencies recommended that health care providers pause their use of Johnson & Johnson's vaccine until an advisory committee can review six cases in which inoculations were followed by dangerous blood clots. All six occurred in women between the ages of 18 and 48 years old. Most importantly, they were associated with a low concentration of blood platelets.

If there is an associated risk, it's an extremely small one. As of Monday, more than 6.8 million people had received Johnson & Johnson's COVID-19 vaccine.

At a rate of less than one patient in a million, this pause might seem like an excessive overabundance of caution. The agencies won't please anyone with this decision, but they really don't have another option.

Both AstraZeneca's (NASDAQ: AZN) COVID-19 vaccine and Johnson & Johnson's employ a non-replicating virus that delivers genetic instructions. The European Medicines Agency recently said unusual blood clots that present in combination with low platelet levels should be listed as a very rare side effect of AstraZeneca's COVID-19 vaccine after assessing dozens of cases similar to the six reported in association with J&J's vaccine.

Blood clots that break free and travel to the blood vessels that serve the heart and other organ systems can be fatal. Strong blood thinners are standard treatments for dangerous clots, but giving those to patients with low platelet concentrations can be just as dangerous. 

The Advisory Committee on Immunization Practices will meet on Wednesday, so based on its determination, injections with Johnson & Johnson's vaccine could be allowed to resume before the end of the week.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Should you invest $1,000 in Johnson & Johnson right now?

Before you buy Johnson & Johnson shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Johnson & Johnson. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

Happy family watching Netflix together.
International Stock News

Netflix stock gained 21.4% last month. Here's how.

Is Netflix on track for a long blockbuster run? Check out what's fuelling investor excitement about the media-streaming veteran right…

Read more »

An elderly man finds out he's made a mistake.
International Stock News

Warren Buffett's career in review: His worst investment decisions

Despite the wins, Buffett has also made plenty of errors in his long career.

Read more »

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
International Stock News

Warren Buffett's career in review: His best investment decisions

Buffett's best buys are simply astonishing.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

Meta Platforms is ramping up data center and AI investments. Is the growth stock a buy now?

Let's take a look.

Read more »

A head shot of legendary investor Warren Buffett speaking into a microphone at an event.
International Stock News

Berkshire Hathaway stock plunges after Warren Buffett steps down. Is this a golden opportunity to buy?

Investors might be wondering whether they should be buying or selling Berkshire Hathaway stock now.

Read more »

Man with virtual white circles on his eye and AI written on top, symbolising artificial intelligence.
International Stock News

Where Will Alphabet Be in 5 Years?

Today, the lowest-valued stock in the "Magnificent Seven" is Alphabet, and it's not close.

Read more »

Silhouette of CEO standing in conference room looking out at cityscape.
International Stock News

Who is Warren Buffett's successor Greg Abel?

Buffett's successor has been in training for years.

Read more »

A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop.
International Stock News

Do Google's antitrust woes make Alphabet stock a buy, sell, or hold?

In the past year, Google lost two major antitrust cases aimed at the heart of its business.

Read more »